Tuesday, January 28, 2020
Monday, January 27, 2020
Here's the abstract to the study:
Monday, January 20, 2020
The consortium of centers included Johns Hopkins University, Toronto University Health Network, Yale University and Memorial Sloan-Kettering Cancer Center. Using molecular profiling, researchers were able to show that the cellular origin of the cancer was most closely aligned to the fallopian tube region rather than the ovaries. This is significant because in high-risk women, currently the ovaries and the fallopian tubes are generally removed. The ability to preserve the ovaries could reduce the risk of heart disease, osteoporosis and other diseases associated with ovarian resection.
To read more about this study, follow this link.
Monday, January 13, 2020
As we know, ovarian and pancreatic cancer are very difficult to treat because by the time they are diagnosed, they are often late stage.
Houston Methodist and MD Anderson have filed a joint patent for a new monoclonal antibody. (Monoclonal antibodies are cloned from a single parent cell and can mimic a variety of immune functions in cancer treatment.)
MFAP5, a protein secreted in high levels in both these cancers, is a marker of poorer survival rates. Researchers have developed a monoclonal antibody that blocks MFAP5 found in the areas surrounding the tumor cells that feed and support the tumor. Blocking MFAP5 effectively starves the tumor since MFAP5 is associated with sustaining the tumor with nutrients. Without this, these cells are more sensitive to chemo. Phase 1 clinical trials will hopefully start in 2020.
You can read more about this by following this link.